A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Clinical trial NCT03157128 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03157128
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Any Solid Tumor

Start date: 2017-05-02
Primary completion: 2025-02-14
Enrollment: 857

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.